Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
35.00
-0.42 (-1.19%)
Dec 3, 2024, 1:24 PM EST - Market open
Apellis Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cash & Equivalents | 396.86 | 351.19 | 551.8 | 640.19 | 565.78 | 351.99 | Upgrade
|
| Short-Term Investments | 6.82 | 4.35 | 6.51 | 61.04 | 311.87 | - | Upgrade
|
| Cash & Short-Term Investments | 403.69 | 355.54 | 558.31 | 701.23 | 877.65 | 351.99 | Upgrade
|
| Cash Growth | -13.28% | -36.32% | -20.38% | -20.10% | 149.34% | 99.69% | Upgrade
|
| Accounts Receivable | 283.97 | 224.5 | 29.17 | 80.1 | 25 | - | Upgrade
|
| Other Receivables | - | - | 8.71 | - | - | - | Upgrade
|
| Receivables | 283.97 | 224.5 | 37.88 | 80.1 | 25 | - | Upgrade
|
| Inventory | 129.31 | 162.66 | 99.7 | 24 | - | - | Upgrade
|
| Prepaid Expenses | 8.98 | 8.59 | 7.18 | 5.17 | 3.4 | 1.7 | Upgrade
|
| Restricted Cash | 1.37 | 1.11 | 1.27 | 1.56 | 1.27 | - | Upgrade
|
| Other Current Assets | 6.58 | 13.93 | 15.18 | 11.98 | 9.88 | 19.41 | Upgrade
|
| Total Current Assets | 833.9 | 766.33 | 719.52 | 824.05 | 917.19 | 373.1 | Upgrade
|
| Property, Plant & Equipment | 20.44 | 21.09 | 24.9 | 26.08 | 24.52 | 15.77 | Upgrade
|
| Long-Term Accounts Receivable | - | - | 15 | 30 | 18 | - | Upgrade
|
| Other Long-Term Assets | 47.53 | 1.31 | 0.8 | 1.64 | 0.86 | 0.39 | Upgrade
|
| Total Assets | 901.87 | 788.73 | 760.22 | 881.77 | 960.57 | 389.25 | Upgrade
|
| Accounts Payable | 42.73 | 37.52 | 37.34 | 16.91 | 8.48 | 8.36 | Upgrade
|
| Accrued Expenses | 139.84 | 127.81 | 95.14 | 103.24 | 111.94 | 54.78 | Upgrade
|
| Current Portion of Leases | 6.79 | 6.44 | 5.63 | 4.12 | 3.69 | 2.61 | Upgrade
|
| Other Current Liabilities | - | 75.83 | 29.5 | 7.58 | 4.23 | - | Upgrade
|
| Total Current Liabilities | 191.26 | 247.59 | 167.61 | 131.85 | 128.33 | 65.75 | Upgrade
|
| Long-Term Debt | 452.25 | 93.03 | 92.74 | 189.02 | 358.83 | 142.57 | Upgrade
|
| Long-Term Leases | 11.41 | 11.45 | 14.35 | 17.08 | 15.22 | 11.86 | Upgrade
|
| Other Long-Term Liabilities | 9.83 | 242.13 | 315.65 | 345.15 | 253.64 | 134.84 | Upgrade
|
| Total Liabilities | 664.75 | 594.21 | 590.35 | 683.1 | 756.01 | 355.02 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 3,239 | 3,036 | 2,480 | 1,857 | 1,131 | 615.85 | Upgrade
|
| Retained Earnings | -2,999 | -2,837 | -2,309 | -1,657 | -926.35 | -581.47 | Upgrade
|
| Comprehensive Income & Other | -3.14 | -3.54 | -0.88 | -2.09 | -0.12 | -0.15 | Upgrade
|
| Total Common Equity | 237.12 | 194.52 | 169.87 | 198.66 | 204.56 | 34.23 | Upgrade
|
| Shareholders' Equity | 237.12 | 194.52 | 169.87 | 198.66 | 204.56 | 34.23 | Upgrade
|
| Total Liabilities & Equity | 901.87 | 788.73 | 760.22 | 881.77 | 960.57 | 389.25 | Upgrade
|
| Total Debt | 470.45 | 110.93 | 112.71 | 210.22 | 377.73 | 157.03 | Upgrade
|
| Net Cash (Debt) | -66.76 | 244.61 | 445.59 | 491.01 | 499.92 | 194.95 | Upgrade
|
| Net Cash Growth | - | -45.10% | -9.25% | -1.78% | 156.43% | 30.64% | Upgrade
|
| Net Cash Per Share | -0.54 | 2.06 | 4.20 | 5.82 | 6.65 | 3.13 | Upgrade
|
| Filing Date Shares Outstanding | 124.39 | 120.58 | 111.29 | 97.73 | 80.38 | 75.32 | Upgrade
|
| Total Common Shares Outstanding | 122.07 | 119.56 | 110.77 | 97.52 | 76.13 | 63.94 | Upgrade
|
| Working Capital | 642.64 | 518.74 | 551.91 | 692.2 | 788.87 | 307.34 | Upgrade
|
| Book Value Per Share | 1.94 | 1.63 | 1.53 | 2.04 | 2.69 | 0.54 | Upgrade
|
| Tangible Book Value | 237.12 | 194.52 | 169.87 | 198.66 | 204.56 | 34.23 | Upgrade
|
| Tangible Book Value Per Share | 1.94 | 1.63 | 1.53 | 2.04 | 2.69 | 0.54 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.